No survival benefit from the inhibition of renin-angiotensin system in biliary tract cancer

Yousuke Nakai; Hiroyuki Isayama; Takashi Sasaki; Naminatsu Takahara; Kei Saito; Tsuyoshi Takeda; Gyotane Umefune; Tomotaka Saito; Kaoru Takagi; Takeo Watanabe; Tsuyoshi Hamada; Rie Uchino; Suguru Mizuno; Keisuke Yamamoto; Hirofumi Kogure; Saburo Matsubara; Natsuyo Yamamoto; Hideaki Ijichi; Keisuke Tateishi; Minoru Tada; Kazuhiko Koike

doi:10.21873/anticanres.11065

No survival benefit from the inhibition of renin-angiotensin system in biliary tract cancer

Yousuke Nakai
, Hiroyuki Isayama
, Takashi Sasaki
, Naminatsu Takahara
, Kei Saito
, Tsuyoshi Takeda
, Gyotane Umefune
, Tomotaka Saito
, Kaoru Takagi
, Takeo Watanabe
, Tsuyoshi Hamada
, Rie Uchino
, Suguru Mizuno
, Keisuke Yamamoto
, Hirofumi Kogure
, Saburo Matsubara
, Natsuyo Yamamoto
, Hideaki Ijichi
, Keisuke Tateishi
, Minoru Tada

Kazuhiko Koike

The University of Tokyo

Research output: Contribution to journal › Article › peer-review

7 Citations (Scopus)

Abstract

Aim: The renin-angiotensin system (RAS) was investigated as a target for cancer treatment. Patients and Methods: A total of 287 patients with biliary tract cancer (BTC) receiving chemotherapy were retrospectively studied to evaluate the role of inhibition of RAS by angiotensin system inhibitors (ASIs). Progression-free survival (PFS) and overall survival (OS) were compared between 74 patients with hypertension, on ASIs (ASI group), 50 patients with hypertension not on ASIs (non-ASI with HT group) and 163 patients without hypertension (non-HT group). Interactions between the use of ASIs and various subgroups were explored. Results: The median PFS was 3.6, 3.9 and 4.6 months (p=0.495) and the median OS was 11.6, 10.9 and 13.1 months (p=0.668), respectively. The use of ASIs was not associated with OS (hazard ratio 1.00, p=0.975) and no subgroups with better survival were identified. Conclusion: No survival benefit from ASIs was observed in BTC.

Original language	English
Pages (from-to)	4965-4970
Number of pages	6
Journal	Anticancer Research
Volume	36
Issue number	9
DOIs	https://doi.org/10.21873/anticanres.11065
Publication status	Published - Sept 2016
Externally published	Yes

Keywords

Angiotensin system inhibitor
Biliary tract cancer
Chemotherapy
Renin-angiotensin system

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.21873/anticanres.11065

Cite this

Nakai, Y., Isayama, H., Sasaki, T., Takahara, N., Saito, K., Takeda, T., Umefune, G., Saito, T., Takagi, K., Watanabe, T., Hamada, T., Uchino, R., Mizuno, S., Yamamoto, K., Kogure, H., Matsubara, S., Yamamoto, N., Ijichi, H., Tateishi, K., ... Koike, K. (2016). No survival benefit from the inhibition of renin-angiotensin system in biliary tract cancer. Anticancer Research, 36(9), 4965-4970. https://doi.org/10.21873/anticanres.11065

@article{8af17daa66f141818abca00a15196071,

title = "No survival benefit from the inhibition of renin-angiotensin system in biliary tract cancer",

abstract = "Aim: The renin-angiotensin system (RAS) was investigated as a target for cancer treatment. Patients and Methods: A total of 287 patients with biliary tract cancer (BTC) receiving chemotherapy were retrospectively studied to evaluate the role of inhibition of RAS by angiotensin system inhibitors (ASIs). Progression-free survival (PFS) and overall survival (OS) were compared between 74 patients with hypertension, on ASIs (ASI group), 50 patients with hypertension not on ASIs (non-ASI with HT group) and 163 patients without hypertension (non-HT group). Interactions between the use of ASIs and various subgroups were explored. Results: The median PFS was 3.6, 3.9 and 4.6 months (p=0.495) and the median OS was 11.6, 10.9 and 13.1 months (p=0.668), respectively. The use of ASIs was not associated with OS (hazard ratio 1.00, p=0.975) and no subgroups with better survival were identified. Conclusion: No survival benefit from ASIs was observed in BTC.",

keywords = "Angiotensin system inhibitor, Biliary tract cancer, Chemotherapy, Renin-angiotensin system",

author = "Yousuke Nakai and Hiroyuki Isayama and Takashi Sasaki and Naminatsu Takahara and Kei Saito and Tsuyoshi Takeda and Gyotane Umefune and Tomotaka Saito and Kaoru Takagi and Takeo Watanabe and Tsuyoshi Hamada and Rie Uchino and Suguru Mizuno and Keisuke Yamamoto and Hirofumi Kogure and Saburo Matsubara and Natsuyo Yamamoto and Hideaki Ijichi and Keisuke Tateishi and Minoru Tada and Kazuhiko Koike",

year = "2016",

month = sep,

doi = "10.21873/anticanres.11065",

language = "English",

volume = "36",

pages = "4965--4970",

journal = "Anticancer Research",

issn = "0250-7005",

publisher = "International Institute of Anticancer Research",

number = "9",

}

Nakai, Y, Isayama, H, Sasaki, T, Takahara, N, Saito, K, Takeda, T, Umefune, G, Saito, T, Takagi, K, Watanabe, T, Hamada, T, Uchino, R, Mizuno, S, Yamamoto, K, Kogure, H, Matsubara, S, Yamamoto, N, Ijichi, H, Tateishi, K, Tada, M & Koike, K 2016, 'No survival benefit from the inhibition of renin-angiotensin system in biliary tract cancer', Anticancer Research, vol. 36, no. 9, pp. 4965-4970. https://doi.org/10.21873/anticanres.11065

TY - JOUR

T1 - No survival benefit from the inhibition of renin-angiotensin system in biliary tract cancer

AU - Nakai, Yousuke

AU - Isayama, Hiroyuki

AU - Sasaki, Takashi

AU - Takahara, Naminatsu

AU - Saito, Kei

AU - Takeda, Tsuyoshi

AU - Umefune, Gyotane

AU - Saito, Tomotaka

AU - Takagi, Kaoru

AU - Watanabe, Takeo

AU - Hamada, Tsuyoshi

AU - Uchino, Rie

AU - Mizuno, Suguru

AU - Yamamoto, Keisuke

AU - Kogure, Hirofumi

AU - Matsubara, Saburo

AU - Yamamoto, Natsuyo

AU - Ijichi, Hideaki

AU - Tateishi, Keisuke

AU - Tada, Minoru

AU - Koike, Kazuhiko

PY - 2016/9

Y1 - 2016/9

N2 - Aim: The renin-angiotensin system (RAS) was investigated as a target for cancer treatment. Patients and Methods: A total of 287 patients with biliary tract cancer (BTC) receiving chemotherapy were retrospectively studied to evaluate the role of inhibition of RAS by angiotensin system inhibitors (ASIs). Progression-free survival (PFS) and overall survival (OS) were compared between 74 patients with hypertension, on ASIs (ASI group), 50 patients with hypertension not on ASIs (non-ASI with HT group) and 163 patients without hypertension (non-HT group). Interactions between the use of ASIs and various subgroups were explored. Results: The median PFS was 3.6, 3.9 and 4.6 months (p=0.495) and the median OS was 11.6, 10.9 and 13.1 months (p=0.668), respectively. The use of ASIs was not associated with OS (hazard ratio 1.00, p=0.975) and no subgroups with better survival were identified. Conclusion: No survival benefit from ASIs was observed in BTC.

AB - Aim: The renin-angiotensin system (RAS) was investigated as a target for cancer treatment. Patients and Methods: A total of 287 patients with biliary tract cancer (BTC) receiving chemotherapy were retrospectively studied to evaluate the role of inhibition of RAS by angiotensin system inhibitors (ASIs). Progression-free survival (PFS) and overall survival (OS) were compared between 74 patients with hypertension, on ASIs (ASI group), 50 patients with hypertension not on ASIs (non-ASI with HT group) and 163 patients without hypertension (non-HT group). Interactions between the use of ASIs and various subgroups were explored. Results: The median PFS was 3.6, 3.9 and 4.6 months (p=0.495) and the median OS was 11.6, 10.9 and 13.1 months (p=0.668), respectively. The use of ASIs was not associated with OS (hazard ratio 1.00, p=0.975) and no subgroups with better survival were identified. Conclusion: No survival benefit from ASIs was observed in BTC.

KW - Angiotensin system inhibitor

KW - Biliary tract cancer

KW - Chemotherapy

KW - Renin-angiotensin system

UR - https://www.scopus.com/pages/publications/84991728142

U2 - 10.21873/anticanres.11065

DO - 10.21873/anticanres.11065

M3 - Article

C2 - 27630357

AN - SCOPUS:84991728142

SN - 0250-7005

VL - 36

SP - 4965

EP - 4970

JO - Anticancer Research

JF - Anticancer Research

IS - 9

ER -

No survival benefit from the inhibition of renin-angiotensin system in biliary tract cancer

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this